eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


4/2017
vol. 16
 
Share:
Share:
abstract:
Review paper

Ulipristal acetate as a treatment option for uterine fibroids

Karolina Piecak
,
Paweł Milart
,
Ewa Woźniakowska
,
Tomasz Paszkowski

Menopause Rev 2017; 16(4): 133-136
Online publish date: 2017/12/30
View full text Get citation
 
PlumX metrics:
Uterine fibroids are the most common benign uterine tumours. Clinical symptoms include abnormal bleeding, pelvic pressure, pelvic pain, infertility and obstetric complications. Approximately one third of women with fibroids will require treatment. The management also depends on the number, size, and location of the fibroids. There are surgical and non-surgical treatment options. The choice of therapy depends on different factors, such as the severity of symptoms, tumour characteristics, age, and wish to preserve the uterus and fertility. There is growing evidence of the main role of progesterone pathways in the pathophysiology of uterine fibroids due to the use of selective progesterone receptor modulators such as ulipristal acetate. The efficacy of long-term intermittent use of UPA was recently demonstrated by randomised controlled studies. There is great demand for alternatives to surgical intervention, especially in women seeking to preserve their fertility. One of these alternatives is ulipristal acetate, which is proven to treat fibroid symptoms effectively.
keywords:

myomas, fibroids, selective progesterone receptor modulators, ulipristal acetate, pharmacological therapy

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.